Open AccessLow Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy
Author(s) -
Matthew J. Akiyama,
Daniel Lipsey,
Moonseong Heo,
Linda Agyemang,
Brianna L. Norton,
Jennifer Hidalgo,
Kiara Lora,
Alain H. Litwin
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciz693
Subject(s) - medicine , viremia , hepatitis c , incidence (geometry) , hepatitis c virus , combination therapy , immunology , virus , physics , optics
Direct-acting antiviral (DAA) therapy is highly effective in people who inject drugs (PWID); however, rates, specific injection behaviors, and social determinants associated with hepatitis C virus (HCV) reinfection following DAA therapy among PWID on opioid agonist therapy (OAT) are poorly understood.